Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory agent (IMiD) presented as a tablet for oral use. It treats certain blood cancers such as multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patients.

GNH USA supplies Lenalidomide Zentiva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple myeloma: improves progression‑free and overall survival in eligible patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may achieve cytogenetic remission. - Mantle cell lymphoma: contributes to disease control when combined with other agents in suitable patients.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: decreased neutrophil count leading to infection risk. - Thrombocytopenia: reduced platelet levels, increasing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe rash or Stevens‑Johnson syndrome: extensive skin reactions. - Hepatic toxicity: elevated liver enzymes or liver injury.

Before initiating therapy, several safety considerations are required. - Pregnancy: contraindicated; Category X, avoid use in pregnant women. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: evaluate kidney function; dose adjustment may be needed. - Drug interactions: review concomitant medications for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct light.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Live vaccines: increased risk of infection due to immunomodulation. - Immunosuppressants (e.g., cyclosporine): may amplify toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk, monitor INR. - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - NSAIDs: additive risk of thrombocytopenia and gastrointestinal bleeding.